The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).
 
Suthee Rapisuwon
Stock and Other Ownership Interests - Cardiff Oncology
Honoraria - General Dynamics Information Technology (GDIT)
Consulting or Advisory Role - Castle Biosciences; Replimune
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Aura Biosciences; Bristol-Myers Squibb/Celgene; Castle Biosciences; Chimeron Bio; Delcath Systems; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; Immunocore; InxMed; Iovance Biotherapeutics; Merck; Oncosec; Pierre Fabre; PureTech; Regeneron; Rgenix; Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
George Ansstas
No Relationships to Disclose
 
Katy K. Tsai
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Leonel Fernando Hernandez-Aya
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Massive Bio; Replimune; Replimune
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); immatics (Inst); immatics (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); Polynoma (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Castle Biosciences; Sanofi/Regeneron
 
Shaheer Khan
Consulting or Advisory Role - Replimune
Research Funding - Incyte (Inst)
 
Sunandana Chandra
Honoraria - Array BioPharma; Bristol Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); exicure (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
J. William Harbour
No Relationships to Disclose
 
Jeffrey A. Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
Research Funding - Werewolf Pharma (Inst)
 
Adil Daud
Stock and Other Ownership Interests - Neuvogen; Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Genoptix; GlaxoSmithKline; Merck; Oncosec; Pfizer
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Christina Decatur
Employment - University of Miami
Honoraria - Castle Biosciences
Research Funding - University of Miami
Travel, Accommodations, Expenses - Castle Biosciences
 
Deniz Ozisik
No Relationships to Disclose
 
Ming Tony Tan
No Relationships to Disclose
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pliant; Pyxis; Sanofi; Scholar Rock; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Sapna Pradyuman Patel
Honoraria - Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; Delcath Systems; IDEAYA Biosciences; immatics; Immunocore; MSD; Novartis; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; TriSalus Life Sciences